FIA
IBRX icon

Foundations Investment Advisors’s ImmunityBio IBRX Stock Holding History

Foundations Investment Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$283K Buy
32,376
+117
+0.4% +$886 ﹤0.01% 994
2026
Q1 		$247K Buy
32,259
+442
+1% +$3.03K ﹤0.01% 992
2025
Q4 		$63K Buy
+31,817
New +$72.1K ﹤0.01% 1097

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Foundations Investment Advisors's IBRX Position: Q2 2026 in Review

Foundations Investment Advisors increased its ImmunityBio (IBRX) stake by 0.36% in Q2 2026, buying an estimated $886 and bringing the position to 32,376 shares worth $283K. The position accounts for ﹤0.01% of the portfolio, ranked #994.

Foundations Investment Advisors first reported a position in IBRX in Q4 2025 and has held it in 3 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Foundations Investment Advisors held 32,376 shares of ImmunityBio worth $283K as of Q2 2026.
  • Foundations Investment Advisors bought 117 ImmunityBio shares in Q2 2026, an estimated $886.
  • ImmunityBio made up ﹤0.01% of Foundations Investment Advisors's portfolio in Q2 2026, its #994 holding.
  • Foundations Investment Advisors first reported a position in ImmunityBio in Q4 2025 and has held it in 3 quarters since.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Foundations Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.